NCT04155645 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

June 7, 2021

Study Completion Date

June 7, 2021

Conditions

Dyslipidemia

Interventions

DRUG

AZD8233 subcutaneous injection

Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.

DRUG

Placebo

Randomized subjects will receive SC dose of placebo injection.

Trial Locations (7)

Research Site, Brooklyn

Research Site, Port Orange

Research Site, Jacksonville

Research Site, Orlando

Research Site, Glendale

Research Site, Chula Vista

Research Site, La Mesa